The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Influenza Therapeutics Market Research Report 2025
Synopsis
Influenza, commonly known as the flu, is an infectious disease caused by an influenza virus.
The global Influenza Therapeutics market was valued at US$ 6644.2 million in 2023 and is anticipated to reach US$ 9521.1 million by 2030, witnessing a CAGR of 4.8% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Influenza Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Influenza Therapeutics.
Report Scope
The Influenza Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Influenza Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Influenza Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott Laboratories
Astrazeneca PLC
Biocryst Pharmaceuticals, Inc.
Chiron Corporation
CSL Limited
Daiichi Sankyo Co., Ltd.
Glaxosmithkline PLC
Mitsubishi Tanabe Pharma Corporation
Nanotherapeutics Inc.
Protein Sciences Corporation
Roche Holding AG
Sanofi SA
Shionogi & Co., Ltd.
Sinovac Biotech Ltd.
Segment by Type
Vaccines
Drugs
Segment by Application
Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Influenza Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Influenza, commonly known as the flu, is an infectious disease caused by an influenza virus.
The global Influenza Therapeutics market was valued at US$ 6644.2 million in 2023 and is anticipated to reach US$ 9521.1 million by 2030, witnessing a CAGR of 4.8% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Influenza Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Influenza Therapeutics.
Report Scope
The Influenza Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Influenza Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Influenza Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott Laboratories
Astrazeneca PLC
Biocryst Pharmaceuticals, Inc.
Chiron Corporation
CSL Limited
Daiichi Sankyo Co., Ltd.
Glaxosmithkline PLC
Mitsubishi Tanabe Pharma Corporation
Nanotherapeutics Inc.
Protein Sciences Corporation
Roche Holding AG
Sanofi SA
Shionogi & Co., Ltd.
Sinovac Biotech Ltd.
Segment by Type
Vaccines
Drugs
Segment by Application
Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Influenza Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Influenza Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Vaccines
1.2.3 Drugs
1.3 Market by Application
1.3.1 Global Influenza Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Influenza Therapeutics Market Perspective (2019-2030)
2.2 Influenza Therapeutics Growth Trends by Region
2.2.1 Global Influenza Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Influenza Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Influenza Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Influenza Therapeutics Market Dynamics
2.3.1 Influenza Therapeutics Industry Trends
2.3.2 Influenza Therapeutics Market Drivers
2.3.3 Influenza Therapeutics Market Challenges
2.3.4 Influenza Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Influenza Therapeutics Players by Revenue
3.1.1 Global Top Influenza Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Influenza Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Influenza Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Influenza Therapeutics Revenue
3.4 Global Influenza Therapeutics Market Concentration Ratio
3.4.1 Global Influenza Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Influenza Therapeutics Revenue in 2023
3.5 Influenza Therapeutics Key Players Head office and Area Served
3.6 Key Players Influenza Therapeutics Product Solution and Service
3.7 Date of Enter into Influenza Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Influenza Therapeutics Breakdown Data by Type
4.1 Global Influenza Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Influenza Therapeutics Forecasted Market Size by Type (2025-2030)
5 Influenza Therapeutics Breakdown Data by Application
5.1 Global Influenza Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Influenza Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Influenza Therapeutics Market Size (2019-2030)
6.2 North America Influenza Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Influenza Therapeutics Market Size by Country (2019-2024)
6.4 North America Influenza Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Influenza Therapeutics Market Size (2019-2030)
7.2 Europe Influenza Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Influenza Therapeutics Market Size by Country (2019-2024)
7.4 Europe Influenza Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Influenza Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Influenza Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Influenza Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Influenza Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Influenza Therapeutics Market Size (2019-2030)
9.2 Latin America Influenza Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Influenza Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Influenza Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Influenza Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Influenza Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Influenza Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Influenza Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Influenza Therapeutics Introduction
11.1.4 Abbott Laboratories Revenue in Influenza Therapeutics Business (2019-2024)
11.1.5 Abbott Laboratories Recent Development
11.2 Astrazeneca PLC
11.2.1 Astrazeneca PLC Company Detail
11.2.2 Astrazeneca PLC Business Overview
11.2.3 Astrazeneca PLC Influenza Therapeutics Introduction
11.2.4 Astrazeneca PLC Revenue in Influenza Therapeutics Business (2019-2024)
11.2.5 Astrazeneca PLC Recent Development
11.3 Biocryst Pharmaceuticals, Inc.
11.3.1 Biocryst Pharmaceuticals, Inc. Company Detail
11.3.2 Biocryst Pharmaceuticals, Inc. Business Overview
11.3.3 Biocryst Pharmaceuticals, Inc. Influenza Therapeutics Introduction
11.3.4 Biocryst Pharmaceuticals, Inc. Revenue in Influenza Therapeutics Business (2019-2024)
11.3.5 Biocryst Pharmaceuticals, Inc. Recent Development
11.4 Chiron Corporation
11.4.1 Chiron Corporation Company Detail
11.4.2 Chiron Corporation Business Overview
11.4.3 Chiron Corporation Influenza Therapeutics Introduction
11.4.4 Chiron Corporation Revenue in Influenza Therapeutics Business (2019-2024)
11.4.5 Chiron Corporation Recent Development
11.5 CSL Limited
11.5.1 CSL Limited Company Detail
11.5.2 CSL Limited Business Overview
11.5.3 CSL Limited Influenza Therapeutics Introduction
11.5.4 CSL Limited Revenue in Influenza Therapeutics Business (2019-2024)
11.5.5 CSL Limited Recent Development
11.6 Daiichi Sankyo Co., Ltd.
11.6.1 Daiichi Sankyo Co., Ltd. Company Detail
11.6.2 Daiichi Sankyo Co., Ltd. Business Overview
11.6.3 Daiichi Sankyo Co., Ltd. Influenza Therapeutics Introduction
11.6.4 Daiichi Sankyo Co., Ltd. Revenue in Influenza Therapeutics Business (2019-2024)
11.6.5 Daiichi Sankyo Co., Ltd. Recent Development
11.7 Glaxosmithkline PLC
11.7.1 Glaxosmithkline PLC Company Detail
11.7.2 Glaxosmithkline PLC Business Overview
11.7.3 Glaxosmithkline PLC Influenza Therapeutics Introduction
11.7.4 Glaxosmithkline PLC Revenue in Influenza Therapeutics Business (2019-2024)
11.7.5 Glaxosmithkline PLC Recent Development
11.8 Mitsubishi Tanabe Pharma Corporation
11.8.1 Mitsubishi Tanabe Pharma Corporation Company Detail
11.8.2 Mitsubishi Tanabe Pharma Corporation Business Overview
11.8.3 Mitsubishi Tanabe Pharma Corporation Influenza Therapeutics Introduction
11.8.4 Mitsubishi Tanabe Pharma Corporation Revenue in Influenza Therapeutics Business (2019-2024)
11.8.5 Mitsubishi Tanabe Pharma Corporation Recent Development
11.9 Nanotherapeutics Inc.
11.9.1 Nanotherapeutics Inc. Company Detail
11.9.2 Nanotherapeutics Inc. Business Overview
11.9.3 Nanotherapeutics Inc. Influenza Therapeutics Introduction
11.9.4 Nanotherapeutics Inc. Revenue in Influenza Therapeutics Business (2019-2024)
11.9.5 Nanotherapeutics Inc. Recent Development
11.10 Protein Sciences Corporation
11.10.1 Protein Sciences Corporation Company Detail
11.10.2 Protein Sciences Corporation Business Overview
11.10.3 Protein Sciences Corporation Influenza Therapeutics Introduction
11.10.4 Protein Sciences Corporation Revenue in Influenza Therapeutics Business (2019-2024)
11.10.5 Protein Sciences Corporation Recent Development
11.11 Roche Holding AG
11.11.1 Roche Holding AG Company Detail
11.11.2 Roche Holding AG Business Overview
11.11.3 Roche Holding AG Influenza Therapeutics Introduction
11.11.4 Roche Holding AG Revenue in Influenza Therapeutics Business (2019-2024)
11.11.5 Roche Holding AG Recent Development
11.12 Sanofi SA
11.12.1 Sanofi SA Company Detail
11.12.2 Sanofi SA Business Overview
11.12.3 Sanofi SA Influenza Therapeutics Introduction
11.12.4 Sanofi SA Revenue in Influenza Therapeutics Business (2019-2024)
11.12.5 Sanofi SA Recent Development
11.13 Shionogi & Co., Ltd.
11.13.1 Shionogi & Co., Ltd. Company Detail
11.13.2 Shionogi & Co., Ltd. Business Overview
11.13.3 Shionogi & Co., Ltd. Influenza Therapeutics Introduction
11.13.4 Shionogi & Co., Ltd. Revenue in Influenza Therapeutics Business (2019-2024)
11.13.5 Shionogi & Co., Ltd. Recent Development
11.14 Sinovac Biotech Ltd.
11.14.1 Sinovac Biotech Ltd. Company Detail
11.14.2 Sinovac Biotech Ltd. Business Overview
11.14.3 Sinovac Biotech Ltd. Influenza Therapeutics Introduction
11.14.4 Sinovac Biotech Ltd. Revenue in Influenza Therapeutics Business (2019-2024)
11.14.5 Sinovac Biotech Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
